Fidelity SPDR Advertisement
Home > Boards > Free Zone > User's Groups > Mohacsy's Safe Portfolio Member Forum

Orphan Drug Status doesn't assure FDA approval of

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
n4807g Member Profile
Member Level 
Followed By 32
Posts 27,229
Boards Moderated 0
Alias Born 07/08/03
160x600 placeholder
S&P 500, Dow Close At Record Levels
The U.S. stock market rallied on Friday, sending the S&P 500 and Dow Jones Industrial Average into record territory, after a surprise stimulus plan from the Bank of Japan was announced.
Top Equities Stories Of The Day
Omega Healthcare to Buy Aviv REIT
Sony Posts Hefty Loss
Starbucks Sales Growth Disappoints; Delivery Is Coming -- 3rdUpdate
Two Picks to Dig Into Pipelines, Shale Energy -- Barron's
U.S. Stocks, Bonds Dip on Fed Outlook
Twitter Demotes Product Chief Daniel Graf
Byron Wien: Slow Growth Good for Stock Market -- Barron's
Jefferies Expected to Book up to $15 Million Loss on Toms Shoes Debt, Sources Say -- Update
n4807g Member Level  Monday, 04/23/12 12:16:00 PM
Re: FullBoogie post# 60301
Post # of 68670 
Orphan Drug Status doesn't assure FDA approval of the compound being evaluated, it confers certain marketing advantages and tax credits should the drug be approved.

Like most small biotechs CYTR will succeed or fail on the technology they employ. In CYTR's case the delivery system. The near term future of INNO-206 will be clear when they report interim findings of their ongoing 2b trial.

Like all biotechs this is a speculative investment, but I've watched many companies with similar strategies do well. The preliminary data look promising (no guarantee) but as I said in my previous post Abraxane uses Albumin as the entry vehicle in tumors and CYTR uses the same concept.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist